Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1529-8019.2012.01471.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real-World Assessment.
United European Gastroenterol J
December 2024
Division of Gastroenterology and Hepatology, NHC Key Laboratory of Digestive Diseases, State Key Laboratory for Oncogenes and Related Genes, School of Medicine, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China.
Background And Objective: With limited evidence connecting paradoxical inflammatory bowel disease (paradoxical IBD) to the newest biologics and Janus kinase inhibitors, our study aims to investigate the occurrence of paradoxical IBD induced by these agents in treating other immune-mediated inflammatory diseases (IMIDs). We aim to identify associated risk signals, the primary affected population, and the risk profile changes over time.
Methods: We performed disproportionality analysis to evaluate paradoxical IBD risk signals using data from the FDA Adverse Event Reporting System.
Paradoxical Deterioration During Treatment of Tuberculous Meningitis Responded to Infliximab But Not to Steroids.
Eur J Case Rep Intern Med
November 2024
Department of Internal Medicine, University Center of Internal Medicine, Cantonal Hospital Baselland, Liestal, Switzerland.
Unlabelled: Paradoxical deterioration in patients with tuberculous meningitis is a significant diagnostic and treatment challenge. We present the case of a 55-year-old previously healthy male, human immunodeficiency virus (HIV)-negative, presenting with headache, fever, agitation and slurred speech, who was ultimately diagnosed with tuberculous meningoencephalitis confirmed by cerebrospinal fluid polymerase chain reaction positive for complex. After initiation of a standard antitubercular therapy combined with glucocorticoids, the patient experienced an initial neurological improvement.
View Article and Find Full Text PDFParadoxical psoriasiform dermatitis involving the nasal mucosa in the setting of infliximab for inflammatory bowel disease.
JAAD Case Rep
October 2024
Department of Dermatology, UMass Memorial Medical Center, Worcester, Massachusetts.
Pyoderma gangrenosum during infliximab in severe hidradenitis suppurativa: A paradoxical event.
Australas J Dermatol
December 2024
Dermatologic Clinic, Department of Medical Science, University of Turin, Turin, Italy.
Tuberculosis and Immune Reconstitution Inflammatory Syndrome in Patients With Inflammatory Bowel Disease and Anti-TNFα Treatment: Insights From a French Multicenter Study and Systematic Literature Review With Emphasis on Paradoxical Anti-TNFα Resumption.
Open Forum Infect Dis
July 2024
Service de Médecine Interne, Hôpital Beaujon, Assistance Publique des Hôpitaux de Paris, Clichy, France.
Article Synopsis
- Anti-TNFα therapy has transformed the treatment of inflammatory bowel disease (IBD), but it poses a risk for developing active tuberculosis (TB) and potential complications like immune reconstitution inflammatory syndrome (IRIS).
- A French retrospective study analyzed 36 IBD patients with TB treated with anti-TNFα, finding a high incidence of disseminated TB and a significant rate of IRIS, particularly in those with miliary TB.
- Most patients resumed anti-TNFα treatment safely after managing TB, with a favorable overall recovery rate, indicating that restarting this therapy can be an effective approach.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!